Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Sarepta, Glu Mobile, Harmony Gold and 2 Other Stocks Are On The Move Today

Page 1 of 2

The markets are mixed on Wednesday as investors remain cautious amid declining crude prices and rising bond yields, which could pressure stocks.

Some stocks are nonetheless gaining ground this morning, including Sarepta Therapeutics Inc (NASDAQ:SRPT), At Home Group Inc. (NYSE:HOME), Array Biopharma Inc (NASDAQ:ARRY), Glu Mobile Inc. (NASDAQ:GLUU) and Harmony Gold Mining Co. (ADR) (NYSE:HMY). Let’s find out what has investors excited about these stocks today and also analyze hedge fund sentiment towards them.

In our backtests, a portfolio of the 15 most popular small-cap stocks generated monthly alpha of 81 basis points, versus 0.7 percentage points posted by hedge funds’ top large- and mega-cap picks (see more details here).

stock-exchange-911619_1920

Harsh Critic of Sarepta’s Drug Departs

Sarepta Therapeutics Inc (NASDAQ:SRPT) has jumped by some 20% today after it was reported that Dr. Ronald Farkas, a harsh critic of Sarepta’s Duchenne muscular dystrophy drug, Eteplirsen, had left the US Food and Drug Administration, making analysts hopeful regarding the drug’s approval. Dr. Farkas was the head of the clinical review team at the FDA. His primary concerns were regarding the randomized controlled trials and open-label extension studies conducted by the sponsor of the drug. Sarepta’s neuromuscular disease treatment has been under review for more than a year. Back in April, a 13-member FDA advisory committee voted against the approval of Eteplirsen, citing a lack of enough evidence to support the drug’s effectiveness against the disease. Out of the hedge funds in Insider Monkey’s database, 20 were long Sarepta Therapeutics Inc (NASDAQ:SRPT) at the end of the second quarter. Joseph Edelman’s Perceptive Advisors owned 3.76 million shares of Sarepta Therapeutics at that time.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Trade (NASDAQ:SRPT) Now!

At Home Group Beats Estimates

Texas-based home décor company At Home Group Inc. (HOME) has gained 4.34% today after the company reported fiscal year 2017 second quarter earnings of $0.13 a share, beating analysts’ consensus estimate of $0.11, while revenue of $188.40 million also blew past the estimates of $183.50 million. Comparable-store sales for the quarter increased by 0.9%. For its full fiscal 2017, At Home Group Inc. (HOME) expects EPS of $0.53-to-$0.56, and revenue of $738 million-to-750 million. The company said its quarterly results, its first as a public company, display its broad consumer appeal and strong execution.

Follow At Home Group Inc.
Trade (HOME) Now!

On the next page, we’ll discuss why Array Biopharma, Glu Mobile and Harmony Gold are in the spotlight today.

Page 1 of 2
Loading Comments...